Eagle Biosciences, Inc. is excited to announce the launch of two new assays to help with the growing epidemic of the COVID-19 virus that is spreading worldwide. The COVID-19 IgG and IgM ELISA’s are successfully validated assays for the qualitative detection of novel coronavirus infected pneumonia cases, suspected clustering cases, and other new coronaviruses in serum or plasma samples (COVID-19) through measurement of the COVID-19 IgM or IgG antibodies.
Assay Background
2019 novel coronavirus (COVID-19) is a single-stranded RNA coronavirus. Comparisons of the genetic sequences of is virus have shown similarities to SARS-CoV and bat coronaviruses. In humans, coronaviruses cause respiratory infections. Coronaviruses are composed of several proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N). Results suggest that the spike protein retains sufficient affinity to the Angiotensin converting enzyme 2 (ACE2) receptor to use it as a mechanism of cell entry. Human to human transmission of coronaviruses is primarily thought to occur among close contacts via respiratory droplets generated by sneezing and coughing. IgM is the first immunoglobulin to be produced in response to an antigen and will be primarily detectable during the early onset of the disease.
Assay Principle
These COVID-19 IgG and IgM ELISA assay kits are designed, developed, and produced for the qualitative measurement of the COVID-19 IgM or COVID-19 IgG antibody in serum. The assays utilizes the “IgM capture” or “IgG capture” methods on microplate based enzyme immunoassay technique.
Assay controls and samples are added to the microtiter wells of a microplate that was coated with an anti-human IgM or IgG specific antibodies. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (HRP) labeled recombinant COVID-19 antigen is added to each well. After an incubation period, an immunocomplex of Anti-hIgM or Anti-hIgG antibody – human COVID-19 IgM or IgG antibody – HRP labeled COVID-19 antigen is formed if there is novel coronavirus IgM or IgG antibody present in the tested materials. The unbound tracer antigen is removed by the subsequent washing step. HRP-labeled COVID-19 antigen tracer bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antigen bound to the coronavirus IgM of IgG on the wall of the microtiter well is proportional to the amount of the coronavirus IgM or IgG antibody level in the tested materials
To learn more, view assay’s here or contact us for questions!
Novel Coronavirus COVID-19 IgM ELISA Kit
Novel Coronavirus COVID-19 IgG ELISA Kit